# Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer

> **NCT06784206** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 30 (estimated)

## Conditions studied

- Small Cell Lung Cancer, Limited Stage
- Hyperfractionated Accelerated Radiotherapy
- Simultaneous Radiotherapy and Chemotherapy

## Interventions

- **DRUG:** Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy

## Key facts

- **NCT ID:** NCT06784206
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2026-08
- **Final completion:** 2028-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06784206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06784206, "Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06784206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*